ZA201003725B - Modulation of protein trafficking - Google Patents

Modulation of protein trafficking

Info

Publication number
ZA201003725B
ZA201003725B ZA2010/03725A ZA201003725A ZA201003725B ZA 201003725 B ZA201003725 B ZA 201003725B ZA 2010/03725 A ZA2010/03725 A ZA 2010/03725A ZA 201003725 A ZA201003725 A ZA 201003725A ZA 201003725 B ZA201003725 B ZA 201003725B
Authority
ZA
South Africa
Prior art keywords
modulation
protein trafficking
trafficking
protein
Prior art date
Application number
ZA2010/03725A
Other languages
English (en)
Inventor
Dan Elbaum
Christine Ellen Bulawa
Michael Devit
Original Assignee
Foldrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foldrx Pharmaceuticals Inc filed Critical Foldrx Pharmaceuticals Inc
Publication of ZA201003725B publication Critical patent/ZA201003725B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2010/03725A 2007-11-07 2010-05-25 Modulation of protein trafficking ZA201003725B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98628207P 2007-11-07 2007-11-07
PCT/US2008/082909 WO2009062118A2 (en) 2007-11-07 2008-11-07 Modulation of protein trafficking

Publications (1)

Publication Number Publication Date
ZA201003725B true ZA201003725B (en) 2011-03-30

Family

ID=40521617

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/03725A ZA201003725B (en) 2007-11-07 2010-05-25 Modulation of protein trafficking

Country Status (10)

Country Link
US (1) US20100331297A1 (enExample)
EP (1) EP2217239A2 (enExample)
JP (1) JP2011503103A (enExample)
CN (1) CN101917999A (enExample)
AU (1) AU2008323694A1 (enExample)
BR (1) BRPI0820342A2 (enExample)
CA (1) CA2705303A1 (enExample)
EA (1) EA201070572A1 (enExample)
WO (1) WO2009062118A2 (enExample)
ZA (1) ZA201003725B (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
DK2358720T3 (en) * 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
DE102009004245A1 (de) * 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
MX2011013816A (es) 2009-06-29 2012-04-11 Incyte Corp Pirimidinonas como inhibidores de pi3k.
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP3489236B1 (en) 2009-12-23 2020-09-30 Takeda Pharmaceutical Company Limited Process for the preparation of fused heteroaromatic pyrrolidinones
JP2013516420A (ja) 2009-12-30 2013-05-13 アークル インコーポレイテッド 置換されたピロロ−アミノピリミジン化合物
AU2011209651A1 (en) * 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
US20130045992A1 (en) 2010-01-28 2013-02-21 President And Fellows Of Harvard College Compositions and Methods for Enhancing Proteasome Activity
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US8642606B2 (en) * 2010-09-29 2014-02-04 Plexxikon Inc. ZAP-70 active compounds
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
CA2828483A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
JP5902293B2 (ja) 2011-04-25 2016-04-13 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法
SI2707101T1 (sl) 2011-05-12 2019-06-28 Proteostasis Therapeutics, Inc. Regulatorji proteostaze
WO2012177714A1 (en) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
KR20140048968A (ko) * 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
EP2548878A1 (en) * 2011-07-21 2013-01-23 Laboratorios Del. Dr. Esteve, S.A. Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands
CA2846496C (en) * 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
BR112015006828A8 (pt) 2012-09-26 2019-09-17 Univ California composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
WO2014066835A1 (en) * 2012-10-25 2014-05-01 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
WO2014066836A1 (en) * 2012-10-25 2014-05-01 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
JP6145179B2 (ja) 2013-02-22 2017-06-07 ファイザー・インク ヤヌス関連キナーゼ（ＪＡＫ）の阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US9695166B2 (en) 2014-05-05 2017-07-04 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
MD20160121A2 (ro) * 2014-05-14 2017-05-31 Pfizer Inc. Pirazolopiridine şi pirazolopirimidine
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
ES2750655T3 (es) 2014-08-12 2020-03-26 Pfizer Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
CN104530151A (zh) * 2015-01-15 2015-04-22 佛山市赛维斯医药科技有限公司 一种含硝基苯s-葡萄糖苷结构的化合物及其用途
CN104530153A (zh) * 2015-01-15 2015-04-22 佛山市赛维斯医药科技有限公司 一类苯基s-葡萄糖苷衍生物、其制备方法和在医药上的用途
AU2016222556B2 (en) 2015-02-27 2020-08-27 Incyte Holdings Corporation Salts of Pl3K inhibitor and processes for their preparation
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107709327A (zh) * 2015-06-22 2018-02-16 小野药品工业株式会社 Brk抑制性化合物
WO2017015267A1 (en) 2015-07-20 2017-01-26 Genzyme Corporation Colony stimulating factor-1 receptor (csf-1r) inhibitors
LV15201B (lv) 2015-08-31 2017-07-20 Latvijas Organiskās Sintēzes Institūts Ibrutiniba izejvielas iegūšanas paņēmiens
CN105198887B (zh) * 2015-09-23 2017-07-28 上海泰坦科技股份有限公司 具有生物活性吡唑并[3,4‑d]嘧啶类试剂的合成工艺
MX2018004365A (es) * 2015-10-09 2018-08-16 Abbvie Sarl Combinaciones de potenciador-corrector utiles en el tratamiento de fibrosis quistica.
NZ741223A (en) * 2015-10-09 2023-03-31 Galapagos Nv N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
GB201521109D0 (en) * 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
KR102742235B1 (ko) * 2016-02-12 2024-12-13 파맥시스 엘티디 라이실 옥시다제의 할로알릴아민 인돌 및 아자인돌 유도체 억제제 및 이의 용도
TN2018000287A1 (en) * 2016-02-15 2020-01-16 Hopitaux Paris Assist Publique Use of stiripentol and their derivatives for decreasing urinary oxalate concentration in an individual
US11208411B2 (en) 2016-03-17 2021-12-28 The Regents Of The University Of California Compositions and methods for treating parasitic diseases
CN107513068A (zh) * 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
EP3504213A4 (en) 2016-08-24 2020-01-15 ArQule, Inc. AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHOD FOR USE THEREOF
IL248028B (en) 2016-09-25 2022-02-01 Univ Bar Ilan Wasp-protecting small molecules, preparations containing them and their uses for methods in the treatment of Wiskott-Aldrich syndrome and x-linked thrombocytopenia
MX2021012639A (es) * 2016-11-18 2022-10-03 Cystic Fibrosis Found Pirrolopirimidinas como potenciadores de cftr.
MY192084A (en) 2016-11-28 2022-07-26 Jiangsu Hengrui Medicine Co Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
CN110300589B (zh) * 2016-12-16 2023-03-10 囊性纤维化基金会 作为cftr增效剂的双环异杂芳基衍生物
TW201837040A (zh) * 2017-03-15 2018-10-16 美商微拉製藥公司 Cdpk1抑制劑及與其相關之組合物及方法
AR112695A1 (es) * 2017-08-17 2019-11-27 Vyera Pharmaceuticals Llc Inhibidores de cdpk1, composiciones y métodos relacionados con los mismos
FR3075795A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075794A1 (fr) * 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
CN111630054B (zh) * 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
BR112020023875A2 (pt) * 2018-05-25 2021-02-09 Jiangsu Hengrui Medicine Co., Ltd. sal de cloridrato, formas cristalinas, métodos de preparação, composição farmacêutica, e usos do sal e das formas cristalinas
CN110526918B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的晶型及制备方法
CN110526917B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的可药用盐、晶型及其制备方法
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
AU2019282098B2 (en) 2018-06-04 2023-12-14 Evotec International Gmbh Pyrazolopyrimidine compounds as adenosine receptor antagonists
EP3852763A1 (en) * 2018-09-18 2021-07-28 Société des Produits Nestlé S.A. Src inhibitor compounds for skeletal muscle modulation, methods and uses thereof
US20210347780A1 (en) * 2018-09-19 2021-11-11 Vyera Pharmaceuticals, LLC Cdpk1 inhibitors, compositions, and methods related thereto
KR102706457B1 (ko) 2018-12-06 2024-09-11 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
JP7566753B2 (ja) * 2019-01-03 2024-10-15 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 転写因子ｅｂポリペプチドレベルを増加させるための方法および材料
JP2023547389A (ja) * 2020-10-23 2023-11-10 イルドン ファーマシューティカル カンパニー リミテッド Ｃｆｔｒ調節剤化合物、その組成物及び用途
WO2022133480A1 (en) * 2020-12-18 2022-06-23 Ikena Oncology, Inc. Aryl hydrocarbon receptor (ahr) agonists and uses thereof
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
CA3210764A1 (en) * 2021-03-03 2022-09-09 Grzegorz Sumara Inhibitor of protein kinase d for use in prevention or treatment of hyperlipidemia
CN116514845A (zh) * 2022-01-22 2023-08-01 轩竹生物科技股份有限公司 Usp1抑制剂及其用途
ES3038124T3 (en) * 2023-05-09 2025-10-09 Molecular Horizon S R L Phenylpyrazole insecticide compounds and compositions
WO2025121320A1 (ja) * 2023-12-04 2025-06-12 国立大学法人山口大学 多発性嚢胞腎の予防又は治療剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342501B1 (en) * 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
CA2810339A1 (en) * 2001-08-10 2003-02-20 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
AU2003225933A1 (en) * 2002-03-22 2003-10-13 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO(3,4-d) PYRIMIDINES AS KINASE MODULATORS
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
MXPA05012619A (es) * 2003-05-21 2006-02-08 Univ Texas Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
US20080287405A1 (en) * 2004-05-14 2008-11-20 Thannickal Victor J Compositions and Methods Relating to Protein Kinase Inhibitors
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
EP1831225A2 (en) * 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
US20090270431A1 (en) * 2005-10-19 2009-10-29 The University Of Georgia Research Foundation Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections
CA2647543A1 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
US20100160339A1 (en) * 2007-05-21 2010-06-24 Mayo Foundation For Medical Education And Research Treating pancreatitis

Also Published As

Publication number Publication date
US20100331297A1 (en) 2010-12-30
WO2009062118A3 (en) 2009-12-30
JP2011503103A (ja) 2011-01-27
CA2705303A1 (en) 2009-05-14
AU2008323694A1 (en) 2009-05-14
CN101917999A (zh) 2010-12-15
BRPI0820342A2 (pt) 2015-05-26
WO2009062118A2 (en) 2009-05-14
EP2217239A2 (en) 2010-08-18
EA201070572A1 (ru) 2010-12-30

Similar Documents

Publication Publication Date Title
ZA201003725B (en) Modulation of protein trafficking
PT3118220T (pt) Proteína
GB0700523D0 (en) The Stabilisation Of Proteins
EP2225275A4 (en) PROTEIN FORMULATION
IL207340A0 (en) Stabilized protein compositions
PL2949666T3 (pl) Ludzkie przeciwciała przeciwko alfa-synukleinie
GB2449354B (en) Binding protein
ZA201303957B (en) Melt-blended protein composition
EP2262375A4 (en) GEL BASED ON MILK PROTEIN
IL211670A0 (en) Therapeutic protein formulations
IL202917A0 (en) Thermostabilization of proteins
GB2462761B (en) Protein formulation
GB2466379B (en) Protein stabilizer
GB0816976D0 (en) Protein
ZA200807318B (en) Compounds and methods for modulating protein trafficking
ZA201100019B (en) Variant hhip1 protein and methods and uses thereof
EP2314681A4 (en) MODIFIED BIOTIN BINDING PROTEIN
ZA201109283B (en) Protein
GB0724953D0 (en) Methods of peptide modification
GB0719231D0 (en) Protein
GB0706217D0 (en) Functional protein crystals
GB0818627D0 (en) Protein
GB0720563D0 (en) Protein
GB0914499D0 (en) Protein expression
GB0715325D0 (en) Fertilisation protein